Learn what targeted protein degraders (TPDs) are, how PROTACs harness the ubiquitin–proteasome system to eliminate disease-causing proteins, why degradation can outperform traditional inhibition, and how these therapies are advancing into clinical trials.
Learn what PROTACs (proteolysis-targeting chimeras) are, how they work via the ubiquitin–proteasome system, and why protein degraders can outperform traditional small molecule inhibitors in oncology and beyond.
Learn how PROTACs (Proteolysis Targeting Chimeras) and targeted protein degraders are transforming small molecule drug design by eliminating disease-causing proteins, enabling catalytic, durable pharmacology across oncology, immunology, and other therapeutic areas.
Learn how targeted protein degraders, especially PROTACs, are transforming small molecule drug discovery by degrading disease‑driving proteins, expanding druggable targets beyond classical enzyme and receptor inhibition.